{"name":"Rigel Pharmaceuticals, Inc.","slug":"rigel","ticker":"RIGL","exchange":"NASDAQ","domain":"rigel.com","description":"Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor,","hq":"South San Francisco, CA","founded":0,"employees":"172","ceo":"Raul Rodriguez","sector":"Specialty Pharma","stockPrice":29.09,"stockChange":0.36,"stockChangePercent":1.25,"marketCap":"$538M","metrics":{"revenue":294281984,"revenueGrowth":21.2,"grossMargin":82,"rdSpend":0,"netIncome":367024000,"cash":154955008,"dividendYield":0,"peRatio":1.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Rezlidhia patent cliff ($0.0B at risk)","drug":"Rezlidhia","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Rigel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Rigel Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with net product revenue of $13.1 million and a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Rigel Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Rezlidhia","summary":"Rigel Pharmaceuticals announced a collaboration with AstraZeneca to develop and commercialize Rezlidhia, a treatment for non-small cell lung cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Rezlidhia for Treatment of Non-Small Cell Lung Cancer","summary":"The FDA approved Rezlidhia, a treatment for non-small cell lung cancer, marking a significant milestone for Rigel Pharmaceuticals.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOOVpzdy1vZDNkWFNfakNlQTZoRUIxV0RIWklwbXFXQWFOS09CYWI5aVJsbk5wVkJoYkNWLURqM1RhRl9SNTYxdF9HMm0wMUdBRU43dE9EXzJ6dWhueHg3MElWSmlmTFBSaDFwNDdWRnFzTE42d1BKU2xyQklLbm1GU3Jicnl0Tm15dTUxbWRpU0d6OGtzdWY0ZzBJRzRrWE9POC1WZ0FxRGg5TXFIUlZkZjF0cGw?oc=5","date":"2026-03-27","type":"pipeline","source":"Insider Monkey","summary":"Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil - Insider Monkey","headline":"Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNeXQ0TXFCcldrU2lFR2JSN0ZfdHp1emp6UjFpMDV3Q2J1M1FObG1tSXJyQWxPNlNzQmU0WldXYlBHVENFTDVRelRtZzhkMGpCVWVPWTZ4ODB5S2NsbzQ2X2ZaVGM0eGZFcXZ5S0Jra25yR0ZYWGI5OUhDYU1xZ2llajBB?oc=5","date":"2026-03-04","type":"pipeline","source":"Seeking Alpha","summary":"Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha","headline":"Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUFN2OTNuSWhaQUpmbEdpcUJhclVqRVVoWmFMQ1YzcUoydU03RXBBWXlqUHZuTzBQVUFqRFFXYVRlaHVRSkRKSDlqaG5jN1ZSUU5SdTFRRVdvbGRWY1RoMl94SXlHaFh2bUpFcndqT0VGcDZOcHNka0x1c0Z1YS1XdlFXSkd0SWlmYnV1S1JjQXZpN3NNNWNMX0o5cHJDSlBveEhfRFJWSGtSTWoxbU1nTkFmcV9Yd0ZPTzRaMQ?oc=5","date":"2026-03-03","type":"earnings","source":"The Globe and Mail","summary":"Rigel Pharma (RIGL) Earnings Call Transcript - The Globe and Mail","headline":"Rigel Pharma (RIGL) Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQTW0yM2l4VGQ3SFJLbUVzMmwyMV9VZDV1OWlkNVQyTExwajU5WHFpb1A0eUlYQkRIQ0lGQXZFOEVieFh1REpoZlN4TkdCZUNmU0hpTC1mYmFrQmFfT2lVdG1kV1FTNzZmSjFPQmp2ZzMyTUR3T1JpcGFRTXQ1dE5tU1FnYlMyS1ZfWWhrcWJkM1ltMzgwODNUWjFsdHpUd0E?oc=5","date":"2026-02-24","type":"earnings","source":"Finviz","summary":"Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz","headline":"Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMnFOM2dxVU02V19fd0hDNzdObEVzQVh1UzNMV2tTNHd3MFljQTcwLTVPSmI4ZE1IeWNtZ2FRTktqVEwzZzlTT3FFdThta3dReGw2QVJQNHlhOThJRHR3NEw4STd3aDQxVnlFWVUtUk5HaGNkbWVJbUlqUDhMSzN0MGEtSG5XUTlXY056a3FOYTdJN3ZJWUoycFpJUUwzQXhhUk1FN2VjdjRNUmhLMTZRYTVFOXpTOGJMX0FpZXNjUzY?oc=5","date":"2026-02-24","type":"pipeline","source":"Stock Titan","summary":"Rigel sets March 3 call to review 2025 results and business update - Stock Titan","headline":"Rigel sets March 3 call to review 2025 results and business update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZGhrUXI5eWFacXplVFc4a1d0N2FZT1JlcXNmU0NabHpZYldhbXYtZmtSRHI0YzdENzZwa2JNZGNfT3JSUEZKcnhGWm1rT0tEQ2hCeGxfRWg4bl9JVTBudHZkWmlLMmx2T0c0Q2piVlp4X1hqeGxpMi12U1Rfbmc5SlRldjVXUWFwcUR3NE5R?oc=5","date":"2026-01-16","type":"earnings","source":"Yahoo Finance","summary":"Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 - Yahoo Finance","headline":"Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPS3llVC1Yd3lPZmlKeWh6RlFWcFhoaW93dnE0N09CYmhUT2loRHVPTGhhcWJtX0dFOERYaWstRUQ4UVZwaGppZW95dlRoYzBXUGJBV0ItQkpfaXlfY1JZVTBHWVlKYzJNNnNXNEVWOEhnR19YRlJoYldBUW85NHdjY3NFTkNWbG1MN3B3bEhVMXVFNDZNeFV6TmVDUQ?oc=5","date":"2026-01-01","type":"pipeline","source":"Seeking Alpha","summary":"Rigel Stock: Formulating A Game Plan For 2026 (NASDAQ:RIGL) - Seeking Alpha","headline":"Rigel Stock: Formulating A Game Plan For 2026 (NASDAQ:RIGL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOalQzaF9OQ1BpdlJKM1VjNFJlSXFxa0MzR011NXladjlZakhRWWdweVZyc3NyMEpnTTJJNW1UUUxubUI1eEd4aWh5TGl3WnFfaDNkalFSRW1NeC1BTGtaa2pkV3ZMdFlhSGVET1NFUWdNclk1VE01ZUpBS3RaSktfbHMxY3hVU2hpMGQ1LVlsZXlDZw?oc=5","date":"2025-11-26","type":"earnings","source":"Seeking Alpha","summary":"Rigel Pharma: Q3 Earnings Showcase Robust Growth (NASDAQ:RIGL) - Seeking Alpha","headline":"Rigel Pharma: Q3 Earnings Showcase Robust Growth (NASDAQ:RIGL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOV2tSbmdwUUhOVUFwaE1HRTJiVjdLYVIwNTQwSy1aNjRXU0lqRWJSMGYyVXIwdHhROEd2TjBmcVM0ZlY0SFZqM29LQnp6YTdUeFlaa3dOcTJGZUFfemE4Tl9qZWZqWjNfbVVpdzlSVHVaLWtreE0yZjFSN25ZUW1XenVyU0VuYjJxU2xGLUM2emtkSFZzbVhzSXRuMW5qWHNHbjVZOWVmYUR4RTJzNzMtRXVMZHVrZEV0bW9aRUJkUjVYUDgzVHJUaWpfbnZacXNr?oc=5","date":"2025-11-04","type":"earnings","source":"PR Newswire","summary":"Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire","headline":"Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQel90NGVEdDB0d2hkOS0yRnYza2dsblh6dXpiU212VnpxVnN3YXE3d1BsQmtUYjNRZWtjUnZKQmwwbGpXMkpJSGdXXzlqVmxkVHlScXk5Y0Vpa245NG1DQl9fZmNCSzhuUTlYY1FZanBXVXZWT1NGdEFicEZHajJIVDlhOWdCNUtQYk9lcmsza200TGh1bUFFUENKZ1NPMVdjUm1uUUtvM0FrQ3pwOEZZSnB3?oc=5","date":"2025-09-25","type":"pipeline","source":"Seeking Alpha","summary":"Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion (NASDAQ:RIGL) - Seeking Alpha","headline":"Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion (NASDAQ:RIGL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNZGVIUlZ3NVpsQUozblVDd2c3VlhxZGlZOFM0VktJNmxMczZsWTNmWE9aOUR4cEEzaG4xZ3RCTjVpTE5uTktGcjRoTTNkOU5tdEM0azVoQlU5T1llNU5tNEFVa01aMGJxWkdJLXdFZmRET2t1OFJFUGZ1VjBpbm5IRW95eXRwUQ?oc=5","date":"2025-08-06","type":"earnings","source":"Yahoo Finance","summary":"Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... - Yahoo Finance","headline":"Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQdWc2U0Qyc183V3BQRFZSbGp0WnpkYjFhY0xWTTVGRGI2aS04dl9ZNW5ldks2dEtHclZwci0waVZKMU1ZZ0R0RzVPd1RBUl9yWlhKZVl6YzFrX24ycXF2X0VCLTZLM1ViRjVsWVpyWEZESTNsdWFJWmxZOGxQZU5TMW9jaGJqMXowTmJjajF0anZfNmdweFVDdmU5N3lYczNTZ1J0S1NpcDBhUTU0VXVNVEJWNmFCR1hOS1kwZG04bWExVkQ5LWx0Y3VWYWdWTjJjeVE?oc=5","date":"2025-08-05","type":"earnings","source":"PR Newswire","summary":"Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire","headline":"Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update","sentiment":"neutral"}],"patents":[{"drugName":"Rezlidhia","drugSlug":"sotorasib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Pfizer","Eli Lilly"],"therapeuticFocus":["Oncology"],"financials":null,"yahoo":{"currentPrice":29.09,"previousClose":28.73,"fiftyTwoWeekHigh":52.24,"fiftyTwoWeekLow":15.5,"fiftyTwoWeekRange":"15.5 - 52.24","fiftyDayAverage":31.39,"twoHundredDayAverage":33.05,"beta":1.27,"enterpriseValue":429081024,"forwardPE":6.1,"priceToBook":1.36,"priceToSales":1.83,"enterpriseToRevenue":1.46,"enterpriseToEbitda":3.35,"pegRatio":0,"ebitda":127881000,"ebitdaMargin":43.5,"freeCashflow":74607248,"operatingCashflow":75655000,"totalDebt":53303000,"debtToEquity":13.6,"currentRatio":2.42,"returnOnAssets":23.1,"returnOnEquity":185.9,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":51.2,"targetHighPrice":71,"targetLowPrice":38,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3,"institutionHeldPercent":90.1,"sharesOutstanding":18480019,"floatShares":18178299,"sharesShort":3729897,"shortRatio":9.65,"shortPercentOfFloat":20.2,"epsTrailing":19.48,"epsForward":4.8,"revenuePerShare":16.36,"bookValue":21.38,"officers":[{"age":64,"name":"Mr. Raul R. Rodriguez","title":"President, CEO & Director"},{"age":62,"name":"Mr. Dean L. Schorno CPA","title":"Executive VP & CFO"},{"age":57,"name":"Mr. Raymond J. Furey J.D.","title":"Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary"},{"age":62,"name":"Mr. David A. Santos","title":"Executive VP & Chief Commercial Officer"},{"age":59,"name":"Dr. Lisa  Rojkjaer M.D.","title":"Executive VP & Chief Medical Officer"},{"age":null,"name":"Ms. Julie  Patel","title":"Senior VP of Human Resources"},{"age":50,"name":"Mr. Joseph  Lasaga","title":"Executive VP & Chief Business Officer"},{"age":null,"name":"Mr. Tarek  Sallam","title":"Vice President of Marketing"}],"industry":"Biotechnology","irWebsite":"http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-irhome","website":"https://www.rigel.com","phone":"650 624 1100"}}